^
    Back
    Association details:
    Biomarker:PI16 overexpression
    Cancer:Hepatocellular Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma

    Published date:
    08/10/2020
    Excerpt:
    BCLC staging C (OR = 3.92; 95% CI: 1.31‐12.86, P = .022) and high PI16 (OR = 2.83; 95% CI: 1.16‐11.49, P = .037) were revealed as independent risk factors for disease progression, respectively.
    DOI:
    https://doi.org/10.1002/cam4.3331
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Cancer Med
    Title:

    PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma

    Published date:
    08/10/2020
    Excerpt:
    ...cell cytotoxicity LDH assay showed that PI16 knockdown sensitized MHCC‐97H cells to sorafenib treatment, and PI16 overexpression in HepG2 cells increased its resistance…
    DOI:
    https://doi.org/10.1002/cam4.3331